PT Diagnos Laboratorium Utama Tbk (IDX:DGNS)

Indonesia · Delayed Price · Currency is IDR

296.00

+14.00 (4.96%)

Nov 5, 2026, 3:40 PM WIB

Market Cap	407.00B +124.6%
Revenue (ttm)	180.75B +14.4%
Net Income	1.12B
EPS	0.87
Shares Out	1.38B
PE Ratio	341.12
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,885,500
Open	284.00
Previous Close	282.00
Day's Range	282.00 - 302.00
52-Week Range	140.00 - 382.00
Beta	0.42
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About IDX:DGNS

PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers laboratory tests comprising hemostasis, hepatitis, autoimmune and rheumatology, tumor markers, toxicology, lipid, allergies, TORCH, diabetes, electrolytes-blood gases, respiratory tract infection, pathology anatomy, neonatal screening, hematology, body fluids, feces, specific proteins, DNAnswer genomics, kidney function, liver function, immunology, osteoporosis, thyroid, pharmacogenomic, heart, reproduction and fertility, microbiology,... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2007

Employees 87

Stock Exchange Indonesia Stock Exchange

Ticker Symbol DGNS

Full Company Profile

Financial Performance

In 2025, IDX:DGNS's revenue was 166.62 billion, an increase of 2.18% compared to the previous year's 163.07 billion. Earnings were 2.94 billion, an increase of 292.95%.

Financial Statements